We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,215

Will You, Won't You Join The Biosimilar Patent Dance?
  • Foley & Lardner LLP
  • USA
  • February 21 2017

In the latest dispute surrounding the “patent dance” provisions of the Biologics Price Competition and Innovation Act (BPCIA), Genentech, Inc. has


Federal Circuit Finds "Consisting Of" Requires Reversing Infringement Of Shire Lialda Patent
  • Foley & Lardner LLP
  • USA
  • February 14 2017

The Federal Circuit focused on the “consisting of” language in the claims at issue when it reversed the district court’s finding that Watson’s ANDA


HIPAA for HR - Some Good News for Employers
  • Foley & Lardner LLP
  • USA
  • February 13 2017

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) is a federal law that was enacted to ensure Protection of Individuals’


FDA Hits “Pause” on Regulation of LDTs
  • Foley & Lardner LLP
  • USA
  • February 12 2017

On January 13, 2017, the U.S. Food and Drug Administration (FDA) issued a Discussion Paper on Laboratory Developed Tests (LDTs) (LDTs) (Discussion


Court Rejects Theory Of Derivation Based On FDA Requirement
  • Foley & Lardner LLP
  • USA
  • February 7 2017

The Federal Circuit decision in Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC may be more interesting for what Mylan argued than for


Rand Corporation Issues Report on U.S. Blood System
  • Foley & Lardner LLP
  • USA
  • February 6 2017

“A robust, sustainable blood system is a crucial component of every health care system.” That is how Rand Corporation’s recently issued comprehensive


More Than 25 of New Molecular Entities Approved in 2016 Are Personalized Medicines
  • Foley & Lardner LLP
  • USA
  • February 5 2017

The Personalized Medicine Coalition (PMC) recently reported that for the third year in a row, personalized medicines accounted for more than 25 of


New Hampshire Finalizes Opioid Prescribing Rules
  • Foley & Lardner LLP
  • USA
  • February 1 2017

New Hampshire is starting 2017 with stepped-up efforts to manage its oft-described opioid epidemic. Though the most recent regulations are directed


What To Know About New HHS OIG Exclusion Regs
  • Foley & Lardner LLP
  • USA
  • January 30 2017

On Jan. 12, 2017, the Office of Inspector General of the U.S. Department of Health and Human Services issued the third and final installment of its


Federal Circuit Finds Infringement Under Akami Of Two-Step Method Of Treatment
  • Foley & Lardner LLP
  • USA
  • January 24 2017

In Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., the Federal Circuit affirmed the district court decision finding infringement under Akami of a